1. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression
- Author
-
Mags Beksinska, Khatija Ahmed, Maricianah Onono, Renee Heffron, Maggie Lind, Jen Deese, Jeffrey S. A. Stringer, Ivana Beesham, Echo Trial Team, Charles S. Morrison, Kavita Nanda, Helen Rees, Vinodh A. Edward, Katherine K. Thomas, Thesla Palanee-Phillips, Jared M. Baeten, G Justus Hofmeyr, Neena M. Philip, Timothy D Mastro, and Gonasagrie Nair
- Subjects
0301 basic medicine ,Adult ,viral suppression ,Adolescent ,Depot ,Immunology ,implants ,Physiology ,HIV Infections ,Levonorgestrel ,Medroxyprogesterone Acetate ,Intrauterine device ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,disease progression ,Virology ,Medicine ,Medroxyprogesterone acetate ,Humans ,030212 general & internal medicine ,Viral suppression ,Clinical Trials/Clinical Studies ,Proportional Hazards Models ,business.industry ,hormonal contraception ,Disease progression ,HIV ,Viral Load ,intrauterine device ,Intrauterine Devices, Copper ,CD4 Lymphocyte Count ,DMPA ,030104 developmental biology ,Infectious Diseases ,Hormonal contraception ,Female ,business ,Hiv disease ,medicine.drug - Abstract
Limited data exist on the effects of contraceptives on HIV disease progression. We studied the association between intramuscular injectable depot medroxyprogesterone acetate (DMPA-IM), the copper intrauterine device (IUD), and the levonorgestrel (LNG) implant on markers of HIV disease progression at the time of HIV detection and 3 months postdetection and time from detection to CD4 count
- Published
- 2020